期刊文献+

溶酶体贮积症的分子生物学机制 被引量:3

The molecular biological mechanism of lysosomal storage disorders
下载PDF
导出
摘要 溶酶体贮积症(LSD)是一类遗传性代谢病,由于溶酶体内的酶、激活蛋白、转运蛋白或溶酶体蛋白加工校正酶的缺乏,引起溶酶体功能缺陷,代谢物不能被有效地消化和转运,在溶酶体中过度贮积所导致的疾病。溶酶体贮积症有50多种,临床表现从无明显症状到多器官衰竭甚至早年夭折,病变呈多系统性,表型呈多样性,因而容易被误诊或漏诊。本文综述近年来对溶酶体贮积症的研究进展、溶酶体贮积症的分类及其临床表型特征,并对糖原贮积病Ⅱ型、唾液酸贮积症、粘多糖贮积病的分子生物学机制进行了探讨。 Lysosomal storage disorders (LSD) are a group of inherited metabolic diseases, which are caused by abnormal accumulation of metabolites in lysosomes due to deficiency of lysosomal proteins such as enzymes, activating proteins, transporters, or lysosomal protein processing enzymes. There are more than 50 known lysosomal storage diseases,while the clinical presentations may vary from no symptoms to multiple organ failure or even death in early ages. The pathological changes are usually multi-systemic, resulting in a diversity of clinical phenotypes. Therefore, lysosomal storage diseases are often misdiag- nosed for others. This paper reviews the current advances in studies of lysosomal storage diseases with the focus on classification, clinical presentations, and the molecular biological mechanisms of Pompe's dis- ease, sialidosis and mucopolysaccharidosis.
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 北大核心 2013年第4期359-366,共8页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 广州市科技计划项目(2010Y1-C871)
关键词 溶酶体贮积症 遗传性代谢病 糖原贮积病 唾液酸贮积症 粘多糖病 lysosomal storage disorders inherited metabolic diseases glycogen storage diseases sialidosis mucopolysaccharidosis
  • 相关文献

参考文献28

  • 1FLETCHER J M. Screening for lysosomal storage disor- ders: a clinical perspective [ J ]. J Inherit Metab Dis, 2006,29(2) :405 -408.
  • 2STONE D L, SIDRANSKYE. Hydropsfetalis : lysosomal storage disorders in extremis[J]. Adv Pediatr, 1999,46 (1) :409 -440.
  • 3MYEROWITZR, COSTIGAN F C. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion inthe gene for the alpha-chain of beta-hexosaminidase [ J ]. J Biol Chem, 1988, 263 (35) : 18587 - 18589.
  • 4VELLODI A. Lysosomal storage disorders [ J ]. Br J Haematol, 2004,128:413 - 431.
  • 5MURTHYTEGK, NAGARJUNA S, SATHAR VALI P, et al. Lysosomal storage disorders and treatment [ J ]. Int J Pharm Tech Res, 2010, 2(2) : 1082 -1091.
  • 6NEUFELD E F. Lysosomal storage diseases [ J ]. An Rev Biochem, 1991,60 : 25.7 - 280.
  • 7HIRSCHHORN R, REUSER A J. Glycogen storage dis- ease type II: acid alpha-glucosidase (acid maltase) deft- ciency; The metabolic and molecular bases of inherited disease [ J ]. New York : McGraw-Hill, 2001 : 3389 - 3420.
  • 8LIN C Y, HWANG B, HSIAO K J, et al. Pompe's dis- ease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity [ J ]. J Inherit Metab Dis, 1987, 10(1) :11 -17.
  • 9PINTO R, CASEIRO C, LEMOS M, et al. Prevalence of lysosomal storage diseases in Portugal [ J ]. Eur J Hum Genet, 2004, 12(2) :87 -92.
  • 10AUSEMS M G, VERBIEST J, HERMANS M P, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic coun- selling [ J ]. Eur J Hum Genet, 1999, 7 (6) :713 - 716.

同被引文献21

  • 1吴希如,包新华.溶酶体贮积症的诊断与治疗进展[J].北京大学学报(医学版),2005,37(4):440-444. 被引量:3
  • 2LANGEREIS E J, WAGEMANS T, KULIK W, et al. A multiplex as- say for the diagnosis of mucopoiysaccharidoses and mucolipidoses [J]. PLoS One,2015,10(9) :e0138622.
  • 3DAVE M B, CHAWLA P K, DHERAI A J, et al. Urinary glycosamin- oglyean estimation as a routine clinical service[ J ]. Indian J Clin Bio- ehem ,2015,30 ( 3 ) :293-297.
  • 4TOMATSU S, SHIMADA T, MASON R W, et al. Assay for glycosami- noglycans by tandem mass spectrometry and its applications[ J]. J A- nal Bioanal Tech ,2014 ( Suppl 2 ) :6.
  • 5AHMED A, RUDSER K, KUNIN-BATSON A, et al. Mueopolysaccha- ridosis ( MPS ) physical symptom score : development, reliability, and validity[J]. JIMD Rep,2015. [ Epub ahead of print].
  • 6CLARKE L A, HOLLAK C E. The clinical spectrum and pathophysi- ology of skeletal complications in lysosomal storage disorders [ J ]. Best Pract Res Clin Endocrinol Metab,2015,29(2) :219-235.
  • 7SUN X,LI L,OVERDIER K H,et al. Analysis of total human urinary glycosaminoglycan disaccharides by liquid Chromatography-Tandem mass spectrometry [ J ]. Anal Chem ,2015,87 (12) :6220-6227.
  • 8TOMATSU S, GUTIERREZ M A, ISHIMARU T, et al. Heparan sul- fate levels in mucopolysaccharidoses and mueolipidoses[ J ]. J Inherit Metab Dis,2005,28 ( 5 ) :743-757.
  • 9MACCARANA M, CASU B, LINDAHL U, Minimal sequence in hep- arin/heparan sulfate required for binding of basic fibroblast growth factor[J]. J Biol Chem,1993,268(32) :23898-23905,.
  • 10郭奕斌.黏多糖病的诊断及防治策略[J].中华临床医师杂志(电子版),2009,3(10):22-25. 被引量:10

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部